Globant(US:GLOB) Prnewswire·2025-10-14 14:58Core Insights - The report titled "Transforming Commercial Pharma with Agentic AI" highlights the rapid adoption of AI agents in the pharmaceutical industry, indicating strong momentum and clear priorities for the sector [1][7] Industry Adoption and Trends - A global study involving 250 senior executives from the pharmaceutical, biotech, and bioengineering sectors reveals that nearly 73% of respondents are planning, piloting, or deploying agentic AI initiatives, with some already in production [8] - The adoption of agentic AI is expected to increase significantly over the next 12 to 18 months, with a focus on market intelligence, patient support, compliance, and data integration as the highest-priority use cases [8] Economic Impact - Generative AI is projected to create between $60 billion and $110 billion annually in economic value for the pharmaceutical and medical product industries, positioning agentic AI as a catalyst for transformation [3] Data and Compliance Priorities - A significant 84% of respondents emphasize the importance of data standardization and integration as a high or medium priority to enable AI agents to deliver value [4][8] - Regulatory compliance (51%), data standardization (49%), patient support (46%), and market intelligence (46%) are identified as the top priorities for AI implementation [8] Challenges to Deployment - The main challenges to deploying agentic AI include workflow design/orchestration (60%) and compliance/validation (55%), followed by tech infrastructure (42%) and data governance (38%) [8] Strategic Vision - Industry leaders advocate for viewing agentic AI as an integral part of core business processes rather than a standalone tool, emphasizing the need for human oversight and clear operational guidelines [5][6] - The strategic integration of agentic AI is seen as a historic opportunity to enhance collaboration between technology and human resources, ultimately improving patient outcomes and industry innovation [9]